These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9372 related articles for article (PubMed ID: 11319798)

  • 1. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.
    Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
    Genes Chromosomes Cancer; 2001 Jun; 31(2):107-16. PubMed ID: 11319798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
    Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
    Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
    Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
    Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
    Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
    Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
    Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
    Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
    Bergman A; Einbeigi Z; Olofsson U; Taib Z; Wallgren A; Karlsson P; Wahlström J; Martinsson T; Nordling M
    Eur J Hum Genet; 2001 Oct; 9(10):787-93. PubMed ID: 11781691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
    Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
    Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
    Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.
    van der Velden PA; Sandkuijl LA; Bergman W; Hille ET; Frants RR; Gruis NA
    Genome Res; 1999 Jun; 9(6):575-80. PubMed ID: 10400925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
    Liu L; Dilworth D; Gao L; Monzon J; Summers A; Lassam N; Hogg D
    Nat Genet; 1999 Jan; 21(1):128-32. PubMed ID: 9916806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations.
    Pollock PM; Spurr N; Bishop T; Newton-Bishop J; Gruis N; van der Velden PA; Goldstein AM; Tucker MA; Foulkes WD; Barnhill R; Haber D; Fountain J; Hayward NK
    Hum Mutat; 1998; 11(6):424-31. PubMed ID: 9603434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder effect in spinal and bulbar muscular atrophy (SBMA) in Scandinavia.
    Lund A; Udd B; Juvonen V; Andersen PM; Cederquist K; Ronnevi LO; Sistonen P; Sörensen SA; Tranebjaerg L; Wallgren-Pettersson C; Savontaus ML
    Eur J Hum Genet; 2000 Aug; 8(8):631-6. PubMed ID: 10951525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
    Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
    Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline splicing mutations of CDKN2A predispose to melanoma.
    Loo JC; Liu L; Hao A; Gao L; Agatep R; Shennan M; Summers A; Goldstein AM; Tucker MA; Deters C; Fusaro R; Blazer K; Weitzel J; Lassam N; Lynch H; Hogg D
    Oncogene; 2003 Sep; 22(41):6387-94. PubMed ID: 14508519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
    Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
    Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 469.